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Abstract
Background: In peripheral vascular bypass surgery different synthetic materials are available for
bypass grafting. It is unclear which of the two commonly used materials, polytetrafluoroethylene
(PTFE) or polyester (Dacron®) grafts, is to be preferred. Thus, the aim of this meta-analysis and
systematic review was to compare the effectiveness of these two prosthetic bypass materials
(Dacron® and PTFE).
Methods:  We performed a systematic literature search in MEDLINE, Cochrane-Library –
CENTRAL, EMBASE and other databases for relevant publications in English and German published
between 1999 and 2008. Only randomized controlled trials were considered for inclusion. We
assessed the methodological quality by means of standardized checklists. Primary patency was used
as the main endpoint. Random-effect meta-analysis as well as pooling data in life table format was
performed to combine study results.
Results: Nine randomized controlled trials (RCT) were included. Two trials showed statistically
significant differences in primary patency, one favouring Dacron® and one favouring PTFE grafts,
while 7 trials did not show statistically significant differences between the two materials. Meta-
analysis on the comparison of PTFE vs. Dacron® grafts yielded no differences with regard to
primary patency rates (hazard ratio 1.04 (95% confidence interval [0.85;1.28]), no significant
heterogeneity (p = 0.32, I2 = 14%)). Similarly, there were no significant differences with regard to
secondary patency rates.
Conclusion: Systematic evaluation and meta-analysis of randomized controlled trials comparing
Dacron® and PTFE as bypass materials for peripheral vascular surgery showed no evidence of an
advantage of one synthetic material over the other.
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Background
The prevalence of symptomatic peripheral arterial disease
in the adult population ranges between 0.6% and 9.2%
and increases with age [1,2]. Patients with peripheral arte-
rial disease have an increased risk of cardiovascular mor-
bidity and mortality, showing a similar risk factor profile
to patients with other atherosclerotic diseases. In the non-
pharmacological treatment of symptomatic peripheral
arterial disease, peripheral vascular surgical interventions
such as bypass grafting and endarterectomy play an
important role [3]. The long-term aim of surgical interven-
tions is to prevent amputation of the limb and to reduce
its resulting disability. According to current guidelines,
surgical interventions are indicated for individuals with
symptomatic disease (claudication), significant func-
tional disability, resistance to exercise or pharmacother-
apy, and a reasonable likelihood of symptomatic
improvement [4]. Whereas endarterectomy is an option in
strictly localised disease, bypass grafting is generally used
to circumvent severely stenosed sections of the peripheral
arteries.
Different materials can be used for bypass grafting includ-
ing autologous and homologous grafts from the saphen-
ous vein or the human umbilical vein as well as prosthetic
graft materials such as polytetrafluoroethylene (PTFE) or
polyester (Dacron®) grafts. Most studies so far have shown
that autologous vein is superior to prosthetic graft materi-
als in bypass surgery [5-7]. A recent review comparing
venous and PTFE bypass procedures reported 5-year pri-
mary patency rates of 74% and 39%, respectively [8].
However, almost a third of patients eligible for peripheral
bypass procedures do not have suitable veins, making the
use of prosthetic materials necessary [9]. Also, due to the
high prevalence of cardiovascular co-morbidity, it may be
required to keep suitable autologous veins for potential
future use in coronary artery bypass grafting. The objective
of our systematic review was, therefore, to identify availa-
ble evidence and compare the effectiveness of the pros-
thetic bypass materials Dacron® and PTFE in peripheral
vascular bypass surgery and to perform meta-analyses, if
possible.
Methods
Literature search
A trained librarian performed a comprehensive systematic
literature search for relevant publications using the fol-
lowing databases: AMED, BIOSIS Previews, CAB
Abstracts, CATFILEplus (CATLINE), Cochrane Library –
CDSR, Cochrane Library – CENTRAL, Elsevier BIOBASE,
EMBASE, EMBASE Alert, ETHMED, GeroLit, GLOBAL
Health, HECLINET, IPA, MEDLINE Alert, MEDLINE,
NHS-CRD-DARE, NHS-CRD-HTA (INAHTA), NHS-EED,
SciSearch, and SOMED. The search terms included
"bypass", "revascularization", "artery reconstruction",
"graft", "prosthesis", and "material". The search was per-
formed in February 2005 with an update search per-
formed in MEDLINE and CENTRAL (Cochrane Central
Register of Controlled Trials) for publications until
August 2008. The systematic database search was supple-
mented by manual search of reference lists of included
articles. The inclusion criteria of studies were: (i) rand-
omized controlled trial (RCT) as study design; (ii) com-
parison of polytetrafluoroethylene (PTFE) or polyester
(Dacron®) grafts for peripheral vascular bypass surgery;
(iii) publication in English or German; and (iv) publica-
tion from 1999 to date. We focused on publications of
English language to cover the most important and quali-
tatively high trials therewith (we additionally searched for
articles in German for a potential adaption to the situa-
tion in Germany). We included studies published in and
after 1999 as the purpose of this review was to provide an
overview focusing on the present evidence from more
recent trials.
Excluded were studies due to the following criteria: (i)
case series; (ii) retrospective studies; (iii) studies compar-
ing venous vs. prosthetic graft materials.
Methodological assessment and endpoints
The methodological quality of relevant publications was
assessed using standardized checklists developed by the
German Scientific Working Group "Technology Assess-
ment for Health Care". [10] evaluating the selection proc-
ess of patients, randomization procedure, assessment of
outcomes, drop-out rates, and adequate statistical meth-
ods. The primary outcome for this review was primary pat-
ency, as defined by the authors. According to Rutherford
et al. primary patency should be assessed by objective
methods such as vascular imaging techniques, palpable
pulse, biphasic or triphasic Doppler, segmental limb pres-
sure index, etc. [11]. We here present primary patency
rates as defined and reported in each trial. Secondary out-
comes were secondary patency, graft infection rates, limb
salvage or amputation rates, and perioperative (< 30 days)
mortality as presented in each study.
Statistical analysis
To perform a meta-analysis, study data from accumulated
life tables was extracted from each study where available.
If failure data was given for one or three months intervals
it was combined to yield 6-months interval data for all
studies. Time of event (graft failure) or censoring (with-
drawals) was thus assigned to the end of each 6-months
interval. A Cox proportional hazard model was used to
calculate hazard ratios with their 95% confidence inter-
vals (CI) and standard errors (SE) for the independent var-
iable "material". This was done for each study separately.
In a random-effect meta-analysis these hazard ratios were
then combined with weights according to their standardBMC Surgery 2008, 8:22 http://www.biomedcentral.com/1471-2482/8/22
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error (inverse variance method), yielding an overall haz-
ard ratio (with 95% CI). Heterogeneity was tested using
the chi-squared Q-statistic and inconsistency was quanti-
fied by I2. Life table data was also pooled to provide Kap-
lan-Meier graphs on graft failure events. All analyses were
performed with SAS V9.1.3 (SAS Institute Inc., Cary, NC,
USA) and Review Manager Version 5.0 (Copenhagen: The
Nordic Cochrane Centre, The Cochrane Collaboration,
2008).
Results
We identified a total of 4421 publications in the search
process. Excluding duplicates and non-relevant publica-
tions based on their title and/or abstract resulted in 419
publications for further quality assessment (Fig. 1). Of
these, 9 publications were found to be relevant to the
research question and fulfilled all inclusion criteria [12-20].
All 9 RCT included in our analysis used primary patency
as their main outcome measure. All studies provided a
definition for the term patency in their methods section,
with primary patency usually meaning unassisted/unin-
terrupted patency with no follow-up procedures on the
bypass assessed by objective methods; one study, how-
ever, defined primary patency as assisted primary patency
[12]. Seven studies also reported results on secondary pat-
ency rates. Five studies present limb salvage or amputa-
tion rates, 4 perioperative mortality (<30 days), and 6
graft infection as further outcomes. Most of these end-
points were not defined in detail.
Table 1 gives an overview of study characteristics and
main results of all RCT included in our analysis.
Of the 9 included studies, 7 studies showed no significant
differences between Dacron® and PTFE regarding primary
patency, 1 study showed significantly higher patency rates
for Dacron® after 2 years [20], and 1 study showed signifi-
cantly higher patency rates for PTFE after 2 years [17].
The 7 RCT reporting results on secondary patency yielded
results similar to primary patency rates, e.g. no significant
differences between the prosthetic materials were found
in 6 studies, and 1 study showed significantly higher sec-
ondary patency after 2 years with Dacron® grafts. Of the
studies reporting results regarding limb salvage or ampu-
tation rates, 4 showed no significant difference, whereas 1
showed a significantly better rate for Dacron® grafts. None
of the studies found significant differences in terms of
graft infection or perioperative mortality (<30 days).
Meta-analysis
Meta-analysis was performed for the comparison of
Dacron® vs. PTFE on primary patency for the 5 studies
where adequate data was available [12-14,17,18]. Two
studies provided also data on secondary patency [13,17].
The combined hazard ratios for PTFE vs. Dacron® were
1.04 (95% CI [0.85;1.28]) for primary patency (Fig. 2)
and 1.02 (95% CI [0.65;1.62]) for secondary patency (Fig.
3). There was no significant heterogeneity between the
studies (p = 0.32 and p = 0.24). The Kaplan-Meier curves
of the pooled data reflect the similar efficacy of the mate-
rials regarding both primary and secondary patency (Fig.
4 and Fig. 5).
Discussion
The present meta-analysis indicated that there are no
major differences in primary and secondary patency rates
between the two prosthetic graft materials Dacron® and
PTFE. Of the 9 included studies, one study showed statis-
tically significant higher patency rates for Dacron® after 2
years [20], 1 study showed statistically significant higher
patency rates for PTFE after 2 years [17], while 7 studies
showed no statistically significant differences between the
two materials regarding primary patency [12-16,18,19].
Our study complements a systematic Cochrane review on
femoro-popliteal bypass surgery by Mamode and Scott
comparing saphenous vein graft with PTFE or Dacron®,
human umbilical vein with PTFE, and PTFE vs. Dacron®
[21]. However, only one study comparing PTFE with
Dacron® in above-knee popliteal grafting was identified
[22]. This study by Abbott et al. was published before the
search period of our review. It did not show a significant
difference regarding primary or secondary patency rates at
the 3-year follow-up.
One of the studies in the present review compared gela-
tine-coated Dacron® vs. collagen-coated Dacron® showing
Literature selection process Figure 1
Literature selection process.
Potentially relevant 
publications from
literature search
N=4421
Publications revised by
full text
N=419
Excluded by screening of 
title/abstract for relevance
N=4002
Excluded because not
relevant, or not all 
inclusion or  1 exclusion 
criteria present
N=410
Included publications
N=9BMC Surgery 2008, 8:22 http://www.biomedcentral.com/1471-2482/8/22
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Table 1: Overview of included studies of Dacron® vs. PTFE as bypass materials in peripheral vascular surgery
Author Year Indication Site of 
bypass
Intervent
ion
Addition
al 
intervent
ion
Follow-
up
(years)
N* Primary 
patency
(N = 
number 
of patients 
or grafts 
under 
risk)
Superior 
primary 
patency
Funding
Baseline End of 
study
Johnson 
and Lee 
[12]
1999 disabling 
claudication, 
rest pain or 
tissue 
necrosis
femorof
emoral, 
axillofe
moral, 
axillobife
moral
Dacron® 
vs. PTFE
Aspirin 
650 mg/d
5 419 47 At 1, 3, 5 
years:
- Dacron®: 
79%, 63%, 
50% (N = 
125, 73, 32)
- PTFE: 
77%, 62%, 
47% (N = 
103, 53, 15)
n.s.
(p-value 
not 
reported)
n.r.
Robinso
n et al. 
[13]
1999 disabling 
claudication, 
rest pain or 
tissue 
necrosis
femorop
opliteal 
(above-
knee 
and 
below-
knee)
gelatine-
sealed 
Dacron® 
vs. PTFE
Cephalothi
n, Heparin, 
Aspirin
3 108 19 At 1, 2, 3 
years:
- Dacron®: 
70%, 56%, 
47% 
(N = 27, 18, 
9)
- PTFE: 
72%, 52%, 
52% 
(N = 33, 16, 
10)
n.s.
(p = 0.87)
n.r.
Green et 
al. [14]
2000 superficial 
femoral 
artery 
occlusion
femorop
opliteal 
(above-
knee)
collagen-
impregnat
ed 
Dacron® 
vs. ePTFE
n.r. 5 240 10 At 1, 3, 5 
years::
- Dacron®: 
78%, 65%, 
45% 
(N = 65, 25, 
5)
- PTFE: 
80%, 63%, 
43% 
(N = 66, 21, 
5)
n.s.
(p-value 
not 
reported)
manufact
urer of 
Dacron®
Post et 
al. [15]
2001 indication 
for artificial 
graft of at 
least 20 cm 
length
femorop
opliteal 
(above-
knee 
and 
below-
knee)
unsealed 
Dacron® 
vs. PTFE
Anti-
platelet 
drugs, 
Heparin or 
Coumadin
3 194 50 At 3 years 
(N = grafts 
under risk):
- Dacron®: 
64% (95%-
CI 
[55%;74%], 
N = 28)
- PTFE: 61% 
(95%-CI 
[49%;72%], 
N = 22)
n.s.
(p = 0.89)
manufact
urer of 
Dacron® 
and PTFEBMC Surgery 2008, 8:22 http://www.biomedcentral.com/1471-2482/8/22
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no differences between the study groups [16]. In another
study heparin-bonded Dacron® instead of bare Dacron®
graft material was used. The issue of different coatings
might in itself affect patency outcomes of Dacron® graft.
However this question cannot adequately be assessed at
the moment due to the lack of data.
Only 5 studies presented data in adequate life table for-
mat for performing a meta-analysis. Results of the meta-
Prager 
et al. 
[16]
2003 aortoiliac 
occlusive 
disease
aortoilia
c
gelatine-
coated 
Dacron® 
vs. 
collagen-
coated 
Dacron® 
vs. PTFE
Antibiotics
, Heparin 
70 IU/kg, 
Fraxiparine 
100 mg/kg/
d (bid for 
patients 
with
anastomos
es)
8 149 35 At 5, 8 
years:
- C-
Dacron®: 
89%, 78% 
(N = 24, 11)
- G-
Dacron®: 
92%, 77% 
(N = 26, 11)
- PTFE: 
88%, 79% 
(N = 29, 13)
n.s.
(p > 0.8)
n.r.
Robinso
n and 
Fletcher 
[17]
2003 disabling 
claudication, 
rest pain or 
tissue loss
femorop
opliteal 
(above-
knee 
and 
below-
knee)
fluoropoly
mer-
coated 
Dacron® 
vs. PTFE
Cephalothi
n, Heparin, 
Aspirin
2 129 21 At 6, 12, 24 
month:
- Dacron®: 
50%, 36%, 
36% 
(N = 27, 17, 
9)
- PTFE: 
71%, 56%, 
47% 
(N = 43, 28, 
12)
PTFE
(p = 
0.002)
manufact
urer of 
Dacron® 
and PTFE
Devine 
and 
McCollu
m [18]
2004 occlusive 
arterial 
disease 
(superficial 
femoral or 
popliteal 
artery)
femorop
opliteal 
(above-
knee 
and 
below-
knee)
collagen-
coated, 
heparin-
bonded 
Dacron® 
vs. PTFE
Aspirin 
300 mg/d
5 209 45 At 1, 3, 5 
years:
- Dacron®: 
71%, 54%, 
46% 
(N = 70, 45, 
20)
- PTFE: 
62%, 44%, 
35% 
(N = 62, 42, 
25)
n.s.
(p = 0.05)
n.r.
Eiberg et 
al. [19]
2006 uni-ilia 
occlusive 
disease
femorof
emoral
fluoropassi
vated, 
gelatine-
sealed 
Dacron®
vs. ePTFE
n.r. 2 198 136 At 1, 2 
years:
- PTFE: 
94%, 93% 
(N = 74, 63)
- Dacron®: 
92%, 87% 
(N = 87, 73)
n.s.
(p = 
0.350)
manufact
urer of 
Dacron® 
and PTFE
Jensen et 
al. [20]
2007 chronic 
lower limb 
ischaemia
femorop
opliteal 
(above-
knee)
gelatine-
coated 
Dacron®
vs. PTFE
n.r. 2 413 150 At 2 years:
- Dacron®: 
70% 
(N = 78)
- PTFE: 57% 
(N = 72)
Dacron®
(p = 
0.002)
manufact
urer of 
Dacron®
PTFE: Polytetrafluoroethylene. ePTFE: expanded Polytetrafluoroethylene. IU: international units. d: day. bid: bis in die. n.s.: not significant. n.r.: not 
reported. CI: confidence interval.
* Number of patients or grafts under risk
Table 1: Overview of included studies of Dacron® vs. PTFE as bypass materials in peripheral vascular surgery (Continued)BMC Surgery 2008, 8:22 http://www.biomedcentral.com/1471-2482/8/22
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analysis might change, if more study data could be
included, especially data of the trial by Jensen et al. [20] as
this was the largest trial to date comparing PTFE vs.
Dacron®. However, it should be noted that patient recruit-
ment and surgeries of that trial were performed up to 14
years before publication of the results (2 year follow up).
For the meta-analysis no raw data with actual times of
event or censoring could be used, as only aggregated life
table data was available. This will overestimate event and
censoring times in both groups, but should not have
influenced the comparison of the two graft materials.
In the context of clinical routine care, physicians regularly
face decisions as to which alternative treatment strategies
to recommend and use. Their decisions should be guided
by best possible evidence of previous studies. Hence, sys-
tematic reviews of good quality RCT have evolved as
important tool of decision support. It is important to
note, however, that the RCT included in our systematic
review were limited by a number of methodological limi-
tations, such as rather small sample sizes, different meth-
ods for determining patency rates, a lack of consideration
paid to additional factors that might affect outcomes such
as baseline differences between groups, and inadequate
interpretations of non-significant results. Reporting of
existing baseline differences between the groups in each
trial was heterogeneous. Only 4 studies provided informa-
tion about adjustment for baseline differences as poten-
tially confounding factors [13,14,18,19]. Group
differences at baseline may thus have biased the results. In
4 trials adequate sample size calculations were reported
[15,18-20]. The other trials may have been too small to
detect any differences in the graft materials. In addition,
no trial used equivalence testing to show that both graft
types were similarly effective. All studies described how
primary patency was assessed and defined, and most stud-
ies used recommended objective standard methods [11].
However, differences in patency rates between studies
might have been affected by unequal assessments, while
differences in patency between PTFE or Dacron® grafts
within studies should not be affected (assuming same
Forrest plot of estimated hazard ratios on primary patency comparing Dacron® and PTFE for each study and by random-effect  meta-analysis (PTFE: polytetrafluoroethylene, SE: standard error, CI: confidence interval) Figure 2
Forrest plot of estimated hazard ratios on primary patency comparing Dacron® and PTFE for each study and 
by random-effect meta-analysis (PTFE: polytetrafluoroethylene, SE: standard error, CI: confidence interval).
Forrest plot of estimated hazard ratios on secondary patency comparing Dacron® and PTFE for each study and by random- effect meta-analysis (PTFE: polytetrafluoroethylene, SE: standard error, CI: confidence interval) Figure 3
Forrest plot of estimated hazard ratios on secondary patency comparing Dacron® and PTFE for each study 
and by random-effect meta-analysis (PTFE: polytetrafluoroethylene, SE: standard error, CI: confidence inter-
val).BMC Surgery 2008, 8:22 http://www.biomedcentral.com/1471-2482/8/22
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assessment standards for patients receiving PTFE or
Dacron® grafts within the trial).
Sources of funding were not specified in 4 trials, with the
remaining trials being funded by or having received grants
from bypass graft manufacturers, which might introduce
bias to the results [23,24]. No explicitly independent/
non-manufacturer sponsored trials were found.
In this review only trials published in English or German
were considered for inclusion. Even though we feel to
cover the most important and qualitatively higher trials
with this strategy, this might result in relevant articles and
evidence published in other languages being ignored.
Results might change if a body of evidence from manu-
scripts in other languages would be available. Since 4 of
the 9 includes trials were conducted in non-English speak-
ing countries (Austria, Germany, and Scandinavian coun-
tries), but were published in English, we assume this
might not be the case.
Conclusion
Even in the light of methodological limitations of the
included trials, the present meta-analysis and systematic
review might offer a basis for clinical decision making in
individual patients requiring peripheral vascular surgery.
Between the two prosthetic materials PTFE and Dacron®
no clear advantage of one over the other could be seen.
Further independently funded studies should address the
issue of heparin-bonded grafts as well as the identification
of subgroups of patients, in which there might be a benefit
of one material. Studies should be sufficiently powered to
be able to detect differences or equivalence of PTFE and
Dacron® grafts.
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